59 results
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
13 Jan 20
Adaptimmune Appoints Elliot Norry as Chief Medical Officer and Makes Changes to R&D Leadership
8:42am
Exhibit 99.1
Adaptimmune Appoints Elliot Norry as Chief Medical Officer and Makes Changes to R&D Leadership
- Organizational changes strengthen … . “In addition, we have made changes to our R&D leadership to accelerate how our products move from research to late stage development, including rapid
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
26 Jan 22
Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer
8:05am
as Chief Commercial Officer effective January 31, 2022.
“I am delighted to welcome Cintia to our leadership team. She brings extensive commercial … and leadership abilities will support our continued growth in our mission to design and develop cell therapies for people with cancer,” said Adrian Rawcliffe
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
27 Feb 20
Adaptimmune Reports Fourth Quarter / Full Year 2019 Financial Results and Business Update
7:39am
with Alpine Immune Sciences and Noile-Immune to develop further next-generation products.
Leadership, manufacturing and financial updates strengthen fully … became Chief Patient Supply Officer effective August 1, 2019. In January 2020, a series of changes to the R&D leadership were announced, including
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
27 Jun 19
Departure of Directors or Certain Officers
8:08am
will join the Board of Directors from the same date.
“Following James’ request early last year, the Board has been planning for leadership succession … manufacturing to information management, but also his previous experiences at GSK. I want to thank James for his leadership, energy and drive, which has delivered
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
7 Sep 21
Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies
7:08am
-cell Therapies
- Combining both companies’ cell therapy leadership and expertise, the collaboration covers the research and development of “off … immunology field. This collaboration broadens Adaptimmune’s leadership position in developing allogeneic cell therapies building on our in-depth
8-K
EX-99.1
nhpjyjvo2f b76nm
20 Nov 20
Regulation FD Disclosure
7:36am
8-K
EX-99.1
evp5pwphya 3rhfc8
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
8-K
1oqs 0om5z11ju
13 Jan 20
Adaptimmune Appoints Elliot Norry as Chief Medical Officer and Makes Changes to R&D Leadership
8:42am
8-K
EX-99.1
rch4iwlyxlbb83 avcd
11 Apr 23
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
8:08am
8-K
EX-99.1
vuehp9
18 Feb 20
Adaptimmune Announces Appointment of Gavin Wood as Chief Financial Officer
8:07am
8-K
EX-99.1
e1bmkfn
1 Aug 19
New Executive Team Announced at Adaptimmune
7:22am